Alembic Pharmaceuticals Limited has informed the Exchange regarding a press release dated March 30, 2023, titled "Alembic Pharmaceuticals receives USFDA Final Approval for Brimonidine Tartrate Ophthalmic Solution, 0.15%.".
Alembic Pharmaceuticals Limited has informed the Exchange regarding a press release dated March 30, 2023, titled "Alembic Pharmaceuticals receives USFDA Final Approval for Brimonidine Tartrate Ophthalmic Solution, 0.15%.".